What is EpiBone?
EpiBone operates at the intersection of biotechnology and orthopedics, specializing in the development of personalized bone and cartilage grafts derived from a patient's own stem cells. By moving away from traditional artificial implants, the company provides a biological alternative that integrates seamlessly with the human body. This innovative approach addresses the root causes of skeletal degradation, offering a regenerative pathway for younger, active patients who require long-term, functional solutions rather than temporary mechanical fixes. The company's proprietary bioreactor platform represents a significant shift in how clinicians approach bone repair, positioning EpiBone as a leader in the burgeoning field of tissue engineering.
How much funding has EpiBone raised?
EpiBone has raised a total of $5.3M across 4 funding rounds:
Private Equity
$560K
Debt
$150K
Debt
$341K
Private Equity
$4.3M
Private Equity (2016): $560K with participation from Plum Alley
Debt (2020): $150K led by PPP
Debt (2021): $341K supported by PPP
Private Equity (2025): $4.3M, investors not publicly disclosed
Key Investors in EpiBone
Plum Alley
Plum Alley Ventures is a venture firm that facilitates smart investments in breakthrough technologies aimed at improving the world for humans, industry, and the planet.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for EpiBone?
With the infusion of this latest capital, EpiBone is well-positioned to scale its manufacturing capabilities and accelerate clinical validation processes. The strategic focus will likely shift toward expanding the reach of its regenerative therapies, ensuring that its personalized bone grafts become a standard of care for complex skeletal conditions. As the company matures, the emphasis will remain on optimizing the bioreactor workflow to increase throughput while maintaining the high precision required for patient-specific grafts. This growth phase is critical for establishing long-term market dominance in the orthopedic sector, as the firm transitions from research-heavy development to broader commercial implementation.
See full EpiBone company page
